Cart
sales@molnova.com
BUR1
CAS No. 23000-46-6
BUR1 ( BUR-1; BUR 1; BMP upregulator 1; BMP upregulator-1 )
Catalog No. M27759 CAS No. 23000-46-6
BUR1 is a Saccharomyces cerevisiae cyclin-dependent kinase (CDK) and is homologous to mammalian Cdk9, which functions in transcriptional elongation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 302 | Get Quote |
|
| 10MG | 447 | Get Quote |
|
| 25MG | 714 | Get Quote |
|
| 50MG | 1017 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBUR1
-
NoteResearch use only, not for human use.
-
Brief DescriptionBUR1 is a Saccharomyces cerevisiae cyclin-dependent kinase (CDK) and is homologous to mammalian Cdk9, which functions in transcriptional elongation.
-
DescriptionBUR1 is a Saccharomyces cerevisiae cyclin-dependent kinase (CDK) and is homologous to mammalian Cdk9, which functions in transcriptional elongation.
-
SynonymsBUR-1; BUR 1; BMP upregulator 1; BMP upregulator-1
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorSETD2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number23000-46-6
-
Formula Weight279.3
-
Molecular FormulaC16H17N5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC1CCN(CC1)c1ncnc2n(ncc12)-c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Jennifer Totman, et al. Pharmacologic Inhibition of the Histone Methyltransferase SETD2 with EZM0414 As a Novel Therapeutic Strategy in Relapsed or Refractory Multiple Myeloma and Diffuse Large B-cell Lymphoma.
molnova catalog
related products
-
MBQ-167
MBQ-167 is a dual inhibitor of Rac/Cdc42 (IC50s: 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively).
-
Amt-87
Amt-87 is a HIV latency-reversal agent that reactivates latent HIV at the transcriptional level, promotes phosphorylation of CDK9 T-loop at Thr186.
-
VMY-1-103
A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.
